



GENFIT: Mr. XAVIER GUILLE DES BUTTES APPOINTED TO THE POSITION OF CHAIRMAN OF THE SUPERVISORY BOARD

Lille (France), Cambridge (Mass.), April 10, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) a biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced the appointment of Mr. Xavier Guille des Buttes to the position of Chairman of GENFIT's Supervisory Board until the Shareholders' General Meeting to be held in June. He succeeds Professor Jean-Charles Fruchart.

Xavier Guille des Buttes, 66 years old, is a member of the Supervisory Boards of DIAGAST and FINANCIÈRE DELPHARM. In the course of the last thirty years with SCHERING SA, Xavier Guille des Buttes has held a number of functions, notably Marketing Director, Managing Director of the Pharmaceutical Division and President of the Management Board until June 2006. He is a graduate of the ESSCA University of Angers, the International Commerce Institute (ICI) and the Forecast Management and Controlling Institute (ICG). He has been a member of GENFIT's Supervisory Board since October 18, 2006. Xavier Guille des Buttes is Chevalier of the Legion of Honour.

Jean-François Mouney, Chairman of GENFIT's Management Board, stated: «Professor Jean-Charles Fruchart has played a key role in accompanying the scientific strategy of GENFIT. We warmly thank him for his contribution. On behalf of all of us, I welcome and congratulate Xavier Guille des Buttes. We are looking forward to sharing with him the pleasure of developing the company».

Xavier Guille des Buttes, Chairman of GENFIT's Supervisory Board added: «I accepted this proposal with pride. I thank all the members of the Supervisory Board for their confidence. I intend to continue with enthusiasm the tremendous work that has been done by my predecessor, and to fully take part in GENFIT's success».

About GENFIT:

A biopharmaceutical company, GENFIT studies the deregulation of genes implicated in many of the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with pharmaceutical companies such as SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic and inflammatory diseases. GENFIT's development of proprietary drugs focuses on global cardiovascular risk factors, using a single molecule to simultaneously attack several pathologies (atherosclerosis, diabetes, obesity, etc.). GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development – development carried out by GENFIT alone or in partnership. GENFIT's lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). (www.genfit.com).

Contacts:

GENFIT

Investors Relations + 33 (0) 3 2016 4000

Investors@Genfit.com

Milestones – Press Relations

Bruno Arabian +33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus.